Fluoxetine
- TRADE NAMES: Adofen; Apo-Fluoxetine; Dom-Fluoxetine; Fluctin; Fluctine; Fludac; Fluoxac; Fluoxeren; Fluxil; Fontex; Prozac (Lilly); Sarafem (Warner Chilcott); Symbyax (Lilly)
- INDICATIONS: Depression, obsessive-compulsive disorder
- CLASS: Antidepressant, Selective serotonin reuptake inhibitor (SSRI)
- HALF-LIFE: 2–3 days
Alprazolam, Amoxapine, Amphetamines, Astemizole, Clarithromycin, Clopidogrel, Clozapine, Desipramine, Deutetrabenazine, Dexibuprofen, Dextroamphetamine, Diethylpropion, Droperidol, Duloxetine, Erythromycin, Gilteritinib, Haloperidol, Iloperidone, Imipramine, Insulin Aspart, Insulin Degludec, Insulin Glargine, Insulin Glulisine, Isocarboxazid, Linezolid, Lithium, MAO inhibitors, Mazindol, Meperidine, Methamphetamine, Midazolam, Moclobemide, Nifedipine, Nortriptyline, Olanzapine, Oliceridine, PEG-Interferon, Phendimetrazine, Phenelzine, Phentermine, Phenylpropanolamine, Phenytoin, Pimozide, Propranolol, Pseudoephedrine, Rasagiline, Risperidone, Selegiline, Serotonin agonists, Sibutramine, St John's Wort, Sumatriptan, Sympathomimetics, Tramadol, Tranylcypromine, Trazodone, Tricyclic antidepressants, Troleandomycin, Tryptophan, Valbenazine, Vortioxetine, Zolmitriptan
PREGNANCY CATEGORY: C
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for Major Depressive Disorder (MDD) and other psychiatric disorders.
Sarafem is not approved for use in pediatric patients with MDD and obsessive compulsive disorder. Symbyax is not approved for use in children and adolescents.
Symbyax is fluoxetine and olanzapine.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fluoxetine in combination with olanzapine in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 09/19/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
